Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: CD47 antigen inhibitors - Paradigm Shift Therapeutics

Next Previous
Search
Drug Profile

Research programme: CD47 antigen inhibitors - Paradigm Shift Therapeutics

Latest Information Update: 20 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Cancer Institute (USA); Paradigm Shift Therapeutics
  • Developer National Center for Advancing Translational Sciences; Paradigm Shift Therapeutics
  • Class Antineoplastics; Radioprotectives; Small molecules
  • Mechanism of Action CD47 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Radiation injuries

Most Recent Events

  • 20 Sep 2023 Research development is ongoing in Radiation-injuries (Prevention) and Cancer in USA (Paradigm Shift Therapeutics website, September 2023)
  • 28 Oct 2020 No recent reports of development identified for preclinical development in Breast-cancer in USA
  • 28 Oct 2020 No recent reports of development identified for research development in Radiation-injuries(Prevention) in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top